Connection
Jose Castillo-Mancilla to Piperazines
This is a "connection" page, showing publications Jose Castillo-Mancilla has written about Piperazines.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.220 |
|
|
|
-
Gartland M, Wang X, Liao Q, Li B, Du F, Krystal M, Tenorio AR, Pierce A, Castillo-Mancilla JR. Exploring the impact of baseline and on-treatment variables on durability of responses to fostemsavir through weeks 96 and 192 in the phase 3 BRIGHTE study. HIV Med. 2026 Mar; 27(3):386-396.
Score: 0.192
-
MacBrayne CE, Castillo-Mancilla J, Burton JR, MaWhinney S, Wagner CB, Micke K, Fey J, Huntley RT, Larson B, Bushman LR, Kiser JJ. Small increase in dolutegravir trough, but equivalent total dolutegravir exposure with simeprevir in HIV/HCV seronegative volunteers. J Antimicrob Chemother. 2018 Jan 01; 73(1):156-159.
Score: 0.028